ProPhase Labs, Inc. (PRPH)
NASDAQ: PRPH · Real-Time Price · USD
0.4222
-0.0121 (-2.79%)
At close: Sep 17, 2025, 4:00 PM EDT
0.4230
+0.0008 (0.19%)
After-hours: Sep 17, 2025, 6:35 PM EDT
ProPhase Labs Revenue
ProPhase Labs had revenue of $1.25M in the quarter ending June 30, 2025, a decrease of -17.09%. This brings the company's revenue in the last twelve months to $5.59M, down -11.64% year-over-year. In the year 2024, ProPhase Labs had annual revenue of $6.77M, down -80.65%.
Revenue (ttm)
$5.59M
Revenue Growth
-11.64%
P/S Ratio
2.30
Revenue / Employee
$58,208
Employees
96
Market Cap
17.54M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.77M | -28.21M | -80.65% |
| Dec 31, 2023 | 34.98M | -87.66M | -71.48% |
| Dec 31, 2022 | 122.65M | 43.61M | 55.17% |
| Dec 31, 2021 | 79.04M | 64.53M | 444.59% |
| Dec 31, 2020 | 14.51M | 4.64M | 46.96% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
PRPH News
- 5 days ago - ProPhase Labs Stockholders Approve All Proposals at September 9, 2025 Special Meeting By More Than 75% In Favor - GlobeNewsWire
- 14 days ago - ProPhase Labs Inc. to Participate in Renmark's Virtual Non-Deal Roadshow Series on Thursday, September 4, 2025 - GlobeNewsWire
- 4 weeks ago - ProPhase Labs, Inc. (PRPH) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - ProPhase Labs Announces Filing of Definitive Proxy Statement and New Date for Special Meeting of Shareholders - GlobeNewsWire
- 5 weeks ago - ProPhase Labs Announces Financial Results for the Three and Six Months Ended June 30, 2025 - GlobeNewsWire
- 5 weeks ago - ProPhase Labs Announces Full USPTO Approval for Issuance of U.S. Patent Protecting Esophageal Adenocarcinoma Risk Assessment - GlobeNewsWire
- 5 weeks ago - ProPhase Labs Inc. to Present Second Quarter 2025 Financial Results on August 13, 2025 - GlobeNewsWire
- 7 weeks ago - ProPhase Labs Announces Special Meeting of Shareholders and Filing of Preliminary Proxy Statement - GlobeNewsWire